BioNTech SE (NASDAQ:BNTX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of BioNTech SE (NASDAQ:BNTX) have been given an average recommendation of “Moderate Buy” by the seventeen research firms that are currently covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation, thirteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $142.72.

BNTX has been the subject of several research analyst reports. Evercore ISI raised BioNTech from an “in-line” rating to an “outperform” rating and increased their price objective for the stock from $110.00 to $125.00 in a research note on Tuesday, November 19th. HC Wainwright reissued a “buy” rating and issued a $150.00 price target on shares of BioNTech in a research report on Monday, November 18th. JPMorgan Chase & Co. lowered their price objective on shares of BioNTech from $124.00 to $122.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 26th. Berenberg Bank initiated coverage on shares of BioNTech in a research report on Tuesday, November 19th. They issued a “buy” rating and a $130.00 target price for the company. Finally, Truist Financial started coverage on shares of BioNTech in a research note on Friday, January 10th. They set a “buy” rating and a $172.00 target price for the company.

Institutional Trading of BioNTech

A number of institutional investors and hedge funds have recently modified their holdings of BNTX. Jones Financial Companies Lllp boosted its holdings in BioNTech by 110.3% during the fourth quarter. Jones Financial Companies Lllp now owns 469 shares of the company’s stock valued at $53,000 after acquiring an additional 246 shares during the period. Planning Capital Management Corp boosted its stake in BioNTech by 45,000.0% during the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock valued at $54,000 after purchasing an additional 450 shares during the period. Quintet Private Bank Europe S.A. grew its holdings in BioNTech by 823.5% in the 4th quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company’s stock valued at $88,000 after buying an additional 700 shares during the last quarter. Allianz SE bought a new position in BioNTech in the 4th quarter worth approximately $90,000. Finally, GAMMA Investing LLC increased its position in BioNTech by 48.2% in the 4th quarter. GAMMA Investing LLC now owns 923 shares of the company’s stock worth $105,000 after buying an additional 300 shares during the period. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Trading Down 3.4 %

NASDAQ BNTX opened at $110.83 on Friday. The firm’s 50 day moving average price is $117.07 and its two-hundred day moving average price is $112.47. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. BioNTech has a twelve month low of $76.53 and a twelve month high of $131.49. The stock has a market cap of $26.57 billion, a price-to-earnings ratio of -52.78 and a beta of 0.30.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.